Active, not recruitingPhase 2NCT04438824
Palbociclib and INCMGA00012 in People With Advanced Liposarcoma
Studying Liposarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Sandra D'Angelo, MDMemorial Sloan Kettering Cancer Center
- Intervention
- INCMGA00012(drug)
- Enrollment
- 42 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (7)
- Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre, New York, United States
Collaborators
Incyte Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04438824 on ClinicalTrials.govOther trials for Liposarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07377747Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal LiposarcomaAustralia and New Zealand Sarcoma Association
- RECRUITINGNCT06436846Genomic Risk in Retroperitoneal SarcomaFox Chase Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04785196APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid TumorsAscentage Pharma Group Inc.
- RECRUITINGNCT04699292International Prospective Registry on Local Treatment Approaches in MLSThe Netherlands Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04557449Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid TumorsPfizer
- ACTIVE NOT RECRUITINGPHASE1NCT03361436Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by SurgeryOHSU Knight Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT03307616Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before SurgeryM.D. Anderson Cancer Center